Bladder transitional cell carcinoma
Not recruitingStudy comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer
Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer
- Disease:Bladder transitional cell carcinoma
- Substances:DocetaxelEnfortumab Vedotin+2
Spain- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Astellas Pharma Global Development Inc.






